Inventor · disambiguated record
Gianluca Rinaldi
Also filed as: RINALDI GIANLUCA
13 granted patents·9 pending applications·55 citations·filing 2008–2022
91Inventor score
Files withFRESENIUS KABI DEUTSCHLAND GMBH15MERCK PATENT GMBH3ARES TRADING SA2AREA TRADING S A1DEL RIO ALESSANDRA1
Top patents by PatentIndex Score
22 records- 0195US10493152B2Adalimumab formulationsFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2015·Granted Dec 3, 2019·10 cites·14 claims
- 0295US10426832B2Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2015·Granted Oct 1, 2019·10 cites·9 claims
- 0394US11752209B2Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2022·Granted Sep 12, 2023·1 cites·11 claims
- 0494US10426833B2Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2015·Granted Oct 1, 2019·10 cites·19 claims
- 0593US10772961B2Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2019·Granted Sep 15, 2020·6 cites·26 claims
- 0692US10729769B2Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2019·Granted Aug 4, 2020·8 cites·17 claims
- 0788US11707524B2Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2021·Granted Jul 25, 2023·1 cites·11 claims
- 0887US11712471B2Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2020·Granted Aug 1, 2023·1 cites·13 claims
- 0986US11752208B2Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2020·Granted Sep 12, 2023·1 cites·6 claims
- 1084US12109267B2Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2022·Granted Oct 8, 2024·0 cites·11 claims
- 1179US11058769B2Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody AvelumabMERCK PATENT GMBH·Filed 2016·Granted Jul 13, 2021·2 cites·40 claims
- 1279US8637021B2Formulations for TACI-immunoglobulin fusion proteinsDEL RIO ALESSANDRA·Filed 2008·Granted Jan 28, 2014·5 cites·21 claims
- 1376US2021308262A1Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2021·Application pending·0 cites
- 1476US2021322551A1Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2021·Application pending·0 cites
- 1572US2021121566A1Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2020·Application pending·0 cites
- 1664US2020155677A1Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2019·Application pending·0 cites
- 1756US2021100903A1Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumabMERCK PATENT GMBH·Filed 2020·Application pending·0 cites
- 1850US2010239580A1Taci-immunoglobulin fusion proteins for treatment of optic neuritisAREA TRADING S A·Filed 2008·Application pending·0 cites
- 1948US2023043290A1Igg:tgfbetarii fusion protein compositionARES TRADING SA·Filed 2020·Application pending·0 cites
- 2042US2020016267A1Aqueous anti-pd-l1 antibody formulationMERCK PATENT GMBH·Filed 2018·Application pending·0 cites
- 2136US10959939B2Liquid pharmaceutical composition of etanercept with lysine and prolineARES TRADING SA·Filed 2015·Granted Mar 30, 2021·0 cites·10 claims
- 2236US2018296674A1Liquid pharmaceutical compositionFRESENIUS KABI DEUTSCHLAND GMBH·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →